Roche launches two new antibodies to identify clinically important mutations in brain cancer patients 

Roche announced the launch of the rabbit monoclonal primary antibody IDH1 R132H (MRQ-67) and the rabbit polyclonal antibody ATRX to determine mutation status in patients diagnosed with brain cancer.A brain tumor forms when there is an abnormal growth of cells in the brain. There are two main types of cells in the brain: Neurons, messengers of the nervous system and glial cells, support and protect neurons and maintain the body’s natural equilibrium. Gliomas, brain tumors that develop from glial cells, are the most common malignant brain tumor in adults.1Gliomas with mutations in the IDH1 and ATRX genes are biologically distinct from tumors that do not carry these mutations. Knowing a patient’s IDH1 and ATRX mutation status allows clinicians to provide personalized patient care based on their specific tumor classification, including an informed prognosis. selection of targeted therapies and inclusion in clinical trials.

“A patient’s IDH1 status helps determine eligibility for clinical trials, which offers more treatment options, and may one day lead to potential targeted therapies for people fighting brain cancer,”

Matt Sause, CEO of Roche Diagnostics.

Timing is crucial for patients battling brain cancer. Patients diagnosed with glioblastoma, the most common type of brain cancer in adults, have a median survival rate of less than one year. Understanding the mutation status of a patient with a glioma will allow clinicians to rapidly determine the optimal course of treatment for that patient and help predict treatment outcomes.Immunohistochemistry is recommended by all major glioma practice guidelines for the determination of IDH1 R132H and ATRX.3-5 mutation status Compared to sequencing, the identification of IDH1 R132H mutations by chemical Immunohistochemistry has been shown to be more accurate, rapid, accessible and cost-effective.6 The IDH1 test can also detect the IDH1 R132H mutation in acute myeloid leukemia (AML).Roche’s IDH1 and ATRX tests are optimized and fully automated on the BenchMark series of instruments. Both tests are now available in the United States. They will likely be available in other non-CE markets later this year and in countries accepting the CE marking by 2024.
Next Post

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

Agios Pharmaceuticals, Inc., the leader in pioneering cellular metabolic therapies for rare diseases, today announced business highlights and financial results for the fourth quarter and fiscal year ended. ends on December 31, 2022. “Over the past year, Agios has made significant progress toward our vision of transforming the lives of […]